Immunotherapy, Sidedness Strategies Enhancing mCRC Treatment – OncLive
OncLive |
Immunotherapy, Sidedness Strategies Enhancing mCRC Treatment
OncLive Combination immunotherapy has shown great promise in patients with metastatic colorectal cancer (mCRC), specifically in the CheckMate-142 study in which nivolumab (Opdivo) plus ipilimumab (Yervoy) yielded a 55% overall response rate and 80% disease … |
